Cooperative Agreement U24CA305456
- This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,500 over 3 years from September 1, 2025 to August 31, 2028 to support the work of lead software engineer Adam Coffman at Washington University in St. Louis. The funding will enable Mr. Coffman to continue his contributions to the development of the CIVIC platform, an open-access, community-driven web resource for clinical interpretation of...
- The University of California, Santa Cruz received a $660,079 Cooperative Agreement award from the National Cancer Institute's (CFDA 93.393) Cancer Cause and Prevention Research program, effective September 1, 2025 through August 31, 2030. The purpose of the award is to maintain and expand the BRCA Exchange, the world's largest public database of genetic variants associated with hereditary breast, ovarian, pancreatic, and prostate cancers. The project will refactor the database infrastructure...
- The National Cancer Institute (NCI), a component of the National Institutes of Health, awarded a $413,509 Cooperative Agreement to Cornell University under the Cancer Biology Research program (CFDA 93.396). The project aims to develop a deep learning-based pipeline named PIONEER to generate comprehensive 3D models of the human interactome, addressing a key unmet need in precision oncology. By integrating PIONEER with the PREPPI pipeline, the project will generate atomic-resolution 3D models...
- This $5,041,790 cooperative agreement award from the National Cancer Institute (NCI), under the Cancer Centers Support Grants program (CFDA 93.397), will fund research projects at the University of California, San Francisco (UCSF) to improve cancer health disparities. The key products and services to be delivered include: Three translational cancer health disparities research projects focused on meningioma, prostate cancer, and breast cancer. The projects aim to evaluate the interplay of...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $675,867 to the Medstar Health Research Institute Inc. to improve the delivery of practical geriatric assessment in community oncology settings. The goal is to increase the use of geriatric assessment, which can help mitigate adverse outcomes for older cancer patients, in clinics with limited specialized resources. The project will compare standard ASCO educational...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $716,623 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Chicago. The award will fund the creation of a multi-tissue DNA methylation data resource using samples from the Genotype-Tissue Expression (GTEx) project. This resource will enable researchers to study variability in human epigenomes and the genetic and environmental...
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This Cooperative Agreement award of $922,755.00 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Massachusetts Medical School (UMASS Medical) aimed at understanding the role of tRNA modification and translational remodeling in cancer progression and metastasis. The project will use advanced RNA mass spectrometry, sequencing, and ribosome profiling techniques to comprehensively catalog tRNA modification dynamics...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $953,922.00 in funding to the Scripps Research Institute in California to conduct research on the links between RNA modifications, codon use, translation, and metabolism in cancer cells. The overall goal is to identify correlations between modification states of the translation apparatus and changes in codon occupancy and translation rate across cancer cell lines, particularly...
- This Cooperative Agreement award of $556,865.00 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Trustees of Tufts College to conduct research on "Stiffness-Mediated Genetic Selection of Cells". The project aims to investigate how the mechanical properties of a cell's substrate can drive the evolution of cell phenotypes and genotypes over sustained culture periods. The research will quantify how cell behaviors like growth, motility, and...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $809,106 to The Washington University from September 1, 2025 through August 31, 2030 to accelerate the expert crowdsourcing of cancer variant interpretation through the CIVIC (Clinical Interpretations of Variants in Cancer) web resource. CIVIC is a community-driven platform that centralizes and standardizes expert-curated interpretations of cancer-related genetic variants to enable widespread adoption of precision oncology. The funding will be used to develop new features that enhance CIVIC's curation interface and accelerate the dissemination of high-quality, expert-verified knowledge on cancer genomic variants to support clinical applications of precision medicine.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/3/25 | ||
| Not listed | $809.1k | 8/29/25 |